: Senesco Technologies, Inc. FD Joel Brooks Brian Ritchie Chief Financial Officer brian.ritchie@fd.com jbrooks@senesco.com 212-850-5600 (732) 296-8400 Senesco Technologies Repo

Senesco Technologies Reports Second Quarter Fiscal 2009

NEW BRUNSWICK, N.J. (February 18,

2009) - Senesco Technologies, Inc. ( Senesco

or the Company ) (NYSE Alternext US: SNT) today reported financial results for

the three months ended December 31, 2008.

three month period ended December 31, 2008 was $1,624,341, or $0.09 per

share, compared with a net loss of $1,049,838 or $0.06 per share, for the three

month period ended December 31, 2007.

This increase in net loss was primarily

the result of an increase in non-cash expenses associated with the outstanding

convertible notes that were issued during the year ended June 30, 2008,

and an increase in operating expenses.

Senesco announced results of maximum

tolerated dose, preclinical toxicology, and efficacy / dose-finding studies in

mice for SNS-01, the Company s multiple myeloma drug candidate.

Senesco s data was presented at the 2008 Annual

Meeting of the American Society of Hematology in a presentation entitled Preclinical

Studies Using Polyethylenimine (PEI) Nanoparticles Complexed with Eukaryotic

Translation Initiation Factor 5A (eIF5A) siRNA and eIF5A Plasmid DNA

Demonstrates Significant Anti-Myeloma Activity in Vitro and in Vivo .

Senesco s preclinical multiple

myeloma data was presented at the 20th EORTC-NCI-AACR Symposium on Molecular

Targets and Cancer Therapeutics .

Senesco appointed Harlan W.

Waksal, M.D., co-founder of ImClone Systems Incorporated, to the Company s

Board of Directors. Dr. Waksal was

instrumental in moving forward the clinical development program for ERBITUX

(cetuximab), an oncology drug now approved in colorectal and head &

Management delivered the Company s corporate

presentation at the 10th Annual Rodman & Renshaw Healthcare

Conference, and the 11th Annual BIO CEO & Investor Conference.

We remain focused on our goal

of filing an Investigational New Drug Application for SNS-01 before the end of

calendar year 2009, said Bruce Galton, President

and CEO of Senesco. The recently

announced results of the maximum tolerated dose, preclinical toxicology, and efficacy

/ dose range finding studies for SNS-01 was an important step toward

accomplishing this goal.

Company did not record any revenue for the three month period ended December 31,

2008. Total revenues of $6,250 for the

three month period ended December 31, 2007 consisted of the amortized

portion of previous milestone payments received in connection with certain

agricultural license agreements.

Research and development

expenses during the three month period ended December 31, 2008 were

$579,286, compared with $392,254 during the three month period ended December 31,

2007, an increase of 47.7%. This

increase was primarily a result of an expansion

of Senesco s human health programs, specifically the Company s multiple myeloma

research program, which was partially offset by a decrease in agricultural

research expenses as a result of a decrease in the allocation of resources from

agriculture to human health at the University of Waterloo.

General and administrative

expenses were $649,056 for the three month period ended December 31, 2008,

compared with $585,851 during the three month period ended December 31,

2007, an increase of 10.8%. This

increase was primarily due to a $64,000 increase in stock based compensation,

an approximately $21,000 increase in professional fees, which were the result of an increase in legal fees, and an

approximately $16,000 increase in director fees, which were due to the Company implementing a cash compensation

plan for non-employee directors beginning July 1, 2008.

2008, Senesco had cash, cash equivalents and investments of $3,615,788, and

working capital of $3,562,743, which the

Company estimates will fund its operations for approximately the next seven

months, as of December 31, 2008.

About Senesco Technologies, Inc.

Senesco Technologies, Inc. is a U.S.

biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to

trigger or delay cell death in mammals (apoptosis) to determine if the

technology is applicable in human medicine. Accelerating apoptosis may

have applications to development of cancer treatments. Delaying apoptosis

may have applications to certain diseases inflammatory and ischemic

diseases. Senesco takes its name from the scientific term for the aging

of plant cells: senescence. Delaying cell breakdown in plants extends

freshness after harvesting, while increasing crop yields, plant size and

resistance to environmental stress. The Company believes that its

technology can be used to develop superior strains of crops without any

modification other than delaying natural plant senescence. Senesco has

partnered with leading-edge companies engaged in agricultural biotechnology and

earns research and development fees for applying its gene-regulating platform

technology to enhance its partners products.

included in this press release are forward-looking statements within the

meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from

such statements expressed or implied herein as a result of a variety of

factors, including, but not limited to: the development of the Company s gene

technology; the approval of the Company s patent applications; the successful

implementation of the Company s research and development programs and joint

ventures; the success of the Company s license agreements; the acceptance by

the market of the Company s products; success of the Company s preliminary

studies and preclinical research; competition and the timing of projects and

trends in future operating performance, the Company s ability to meet its

funding milestones under its financing transaction, the Company s ability to

comply with the continued listing standards of the AMEX, as well as other

factors expressed from time to time in the Company s periodic filings with the

Securities and Exchange Commission (the SEC ).

As a result, this press release should be read in conjunction with the

Company s periodic filings with the SEC.

The forward-looking statements contained herein are made only as of the

date of this press release, and the Company undertakes no obligation to

publicly update such forward-looking statements to reflect subsequent events or